94 related articles for article (PubMed ID: 22318926)
1. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.
Clark PJ; Thompson AJ; Vock DM; Kratz LE; Tolun AA; Muir AJ; McHutchison JG; Subramanian M; Millington DM; Kelley RI; Patel K
Hepatology; 2012 Jul; 56(1):49-56. PubMed ID: 22318926
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Younossi ZM; Stepanova M; Estep M; Negro F; Clark PJ; Hunt S; Song Q; Paulson M; Stamm LM; Brainard DM; Subramanian GM; McHutchison JG; Patel K
J Hepatol; 2016 Jan; 64(1):29-36. PubMed ID: 26341824
[TBL] [Abstract][Full Text] [Related]
3. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.
Sheridan DA; Price DA; Schmid ML; Toms GL; Donaldson P; Neely D; Bassendine MF
Aliment Pharmacol Ther; 2009 Jun; 29(12):1282-90. PubMed ID: 19392865
[TBL] [Abstract][Full Text] [Related]
5. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
Kanda T; Moriyama M
World J Gastroenterol; 2017 Aug; 23(31):5645-5649. PubMed ID: 28883690
[TBL] [Abstract][Full Text] [Related]
8. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
9. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy.
Kuo YH; Chuang TW; Hung CH; Chen CH; Wang JH; Hu TH; Lu SN; Lee CM
J Formos Med Assoc; 2011 Jun; 110(6):363-71. PubMed ID: 21741004
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
Hofer H; Bankl HC; Wrba F; Steindl-Munda P; Peck-Radosavljevic M; Osterreicher C; Mueller C; Gangl A; Ferenci P
Am J Gastroenterol; 2002 Nov; 97(11):2880-5. PubMed ID: 12425563
[TBL] [Abstract][Full Text] [Related]
11. Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis.
Sheridan DA; Shawa IT; Thomas EL; Felmlee DJ; Bridge SH; Neely D; Cobbold JF; Holmes E; Bassendine MF; Taylor-Robinson SD
Sci Rep; 2022 Apr; 12(1):5562. PubMed ID: 35365728
[TBL] [Abstract][Full Text] [Related]
12. Are statins a viable option for the treatment of infections with the hepatitis C virus?
Verpaalen B; Neyts J; Delang L
Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance.
Chang ML; Tsou YK; Hu TH; Lin CH; Lin WR; Sung CM; Chen TH; Cheng ML; Chang KC; Chiu CT; Yeh CT; Pang JH; Shiao MS
PLoS One; 2014; 9(8):e104783. PubMed ID: 25122116
[TBL] [Abstract][Full Text] [Related]
14. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation.
Chang SW; Cheng ML; Shiao MS; Yeh CT; Wang CH; Fan CM; Chiu CT; Chang ML
J Clin Lipidol; 2018; 12(3):756-766. PubMed ID: 29574072
[TBL] [Abstract][Full Text] [Related]
15. Recovery of pan-genotypic and genotype-specific amino acid alterations in chronic hepatitis C after viral clearance: transition at the crossroad of metabolism and immunity.
Chang ML; Cheng ML; Chang SW; Tang HY; Chiu CT; Yeh CT; Shiao MS
Amino Acids; 2017 Feb; 49(2):291-302. PubMed ID: 27830380
[TBL] [Abstract][Full Text] [Related]
16. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
[TBL] [Abstract][Full Text] [Related]
17. Metabolic alterations and hepatitis C: From bench to bedside.
Chang ML
World J Gastroenterol; 2016 Jan; 22(4):1461-76. PubMed ID: 26819514
[TBL] [Abstract][Full Text] [Related]
18. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
[TBL] [Abstract][Full Text] [Related]
19. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
[TBL] [Abstract][Full Text] [Related]
20. The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance.
Chang ML; Hsu CM; Lin CH; Lin CY; Kuo CJ; Huang SW; Chen CW; Cheng HT; Yeh CT; Chiu CT
Nutrients; 2017 Jun; 9(6):. PubMed ID: 28574439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
